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Summary. Background: Targeting factor (F) VIII expression to platelets is a promising gene therapy approach for hemophilia A, and is successful even in the presence of inhibitors. It is well known that platelets play important roles not only in hemostasis, but also in thrombosis and inflammation. Objective: To evaluate whether platelet-FVIII expression might increase thrombotic risk and thereby compromise the safety of this approach. Methods: In this study, platelet-FVIII-expressing transgenic mice were examined either in steady-state conditions or under prothrombotic conditions induced by inflammation or the FV Leiden mutation. Native whole blood thrombin generation assay, rotational thromboelastometry analysis and ferric chloride-induced vessel injury were used to evaluate the hemostatic properties. Various parameters associated with thrombosis risk, including D-dimer, thrombinantithrombin complexes, fibrinogen, tissue fibrin deposition, platelet activation status and activatability, and platelet-leukocyte aggregates, were assessed. Results: We generated a new line of transgenic mice that expressed 30-fold higher levels of platelet-expressed FVIII than are therapeutically required to restore hemostasis in hemophilic mice. Under both steady-state conditions and prothrombotic conditions induced by lipopolysaccharide-mediated inflammation or the FV Leiden mutation, supratherapeutic levels of platelet-expressed FVIII did not appear to beIntroduction Factor (F) VIII replacement is the prevailing therapy for hemophilia A (HA) patients. A major complication in protein replacement therapy, however, is the development of inhibitory antibodies against FVIII (inhibitors) [1] . Alternative treatment options for inhibitor patients, such as immune tolerance induction or treatment with FVIIIbypassing agents, are available, but are very expensive and may reduce quality of life for patients [2] . Because of its monogenic nature, HA is an ideal disease candidate for gene therapy, which might cure the disease if successful. Several gene therapy approaches for the treatment of HA have been described in preclinical and clinical studies [3] [4] [5] . Platelet-targeted FVIII gene therapy has been evaluated by several groups, and appears promising [6] [7] [8] [9] [10] [11] [12] [13] [14] . Our group has previously developed a strategy in which human B-domain-deleted FVIII (hBDDFVIII) expression is driven by the aIIb promoter, resulting in FVIII expression in platelets. This platelet-expressed FVIII is hereafter referred to as 2bF8 [7] [8] [9] [10] [11] [12] . 2bF8 protects hemophilic mice from lethal blood loss upon vessel injury, does not induce inhibitor development, and, importantly, is even successful in the treatment of mice with pre-existing inhibitors [7, 9, 10] . Additionally, 2bF8 gene therapy induces immune tolerance to FVIII, allowing the intravenous infusion of recombinant FVIII protein without the formation of inhibitors [12] . Furthermore, 2bF8 has been shown to restore hemostasis in a larger preclinical model, the hemophilic dog [15] . Hemostatic efficacy in the absence and in the presence of inhibitors has also been demonstrated by expressing FVIII in platelets by use of the glycoprotein (GP) Ib promoter [6, 13, 14] . Thus, targeting FVIII expression to platelets may offer the first permanent hemostatic correction for patients with inhibitors.
Although FVIII is normally expressed in endothelial cells and not in platelets [16, 17] , platelets can express FVIII following platelet-targeted gene therapy. It is known that platelets play important roles not only in hemostasis, but also in thrombosis and inflammation [18] . Although the platelet-targeted FVIII gene therapy approach is successful in restoring hemostasis, it is warranted to evaluate the safety concerns associated with platelet-targeted FVIII expression before this novel approach can be applied to a clinical trial. A higher embolism rate has been reported in a transgenic mouse model expressing FVIII in platelets driven by the GPIb promoter on an exon 16-disrupted FVIIIdeficient background [19] . Whether targeting ectopic expression of FVIII to platelets would cause a potential thrombotic risk has not been investigated.
In this study, we attempted to define the breadth of the therapeutic window and ensure safety by exploring whether supratherapeutic levels of 2bF8 induce a prothrombotic state. We generated a new line of 2bF8 transgenic mice with high levels of platelet-FVIII expression. We found that under both steady-state conditions and prothrombotic conditions induced by lipopolysaccharide (LPS)-mediated inflammation or the FV Leiden (FVL) mutation, supratherapeutic levels of platelet-expressed FVIII did not appear to be thrombogenic. Furthermore, FVIII-expressing platelets were neither hyperactivated nor hyperactivatable upon agonist activation.
Materials and methods

Mice
FVIII
null mice (FVIII exon 17 disrupted) [20] on a C57BL6/129S mixed background were a kind gift from H. Kazazian (University of Pennsylvania School of Medicine). C57BL6/129S mice served as wild-type (WT) controls. Transgenic mice that were on a C57BL6/129S background and expressed high levels of hBDDFVIII in platelets (LV17/18 tg mice) were generated by crossing our previously described LV17 tg and LV18 tg mice [21, 22] . FVL mice were bred in-house and derived from the originally described colony [23] . LV18 tg mice were crossed with FVL mice for studies of 2bF8 on the FVL background in addition to normal levels of mouse FVIII. Animal studies complied with a protocol approved by the Institutional Animal Care and Use Committee of the Medical College of Wisconsin.
LPS challenge
Mice were injected intraperitoneally with LPS (40 mg kg
À1
; Escherichia coli serotype O55:B5; Sigma Aldrich, St Louis, MO, USA) or phosphate-buffered saline (PBS) as control, and this was followed by subcutaneous injection of 700 lL of Lympholyte A (Baxter Healthcare, Deerfield, IL, USA) for supportive care. Blood and tissue samples were obtained 16 h after LPS challenge. One hour before sample harvesting, LPS-challenged mice were intraperitoneally injected with 700 lL of Lympholyte A for supportive care.
Whole blood, plasma and platelet lysate collection
For all coagulation studies, blood of anesthetized mice was drawn from the inferior vena cava (IVC) into 3.8% sodium citrate at a 9 : 1 ratio. To determine platelet counts and hematocrit (HCT), blood was counted on a scil Vet ABC hematologic analyzer (scil animal care company, Gurnee, IL, USA). For genotyping and isolation of platelets, blood was drawn from the retro-orbital plexus into 3.8% sodium citrate at a 9 : 1 ratio. Platelet-poor plasma and platelet lysates were obtained by processing of blood collected from the IVC or retro-orbital bleed, as previously described [9] .
FVIII activity (FVIII:C) assays FVIII:C in platelet lysates was determined with a modified chromogenic assay by use of the Coatest SP4 FVIII kit (DiaPharma Group, West Chester, OH, USA), as previously described [7] . Dilutions of hBDDFVIII (recombinant human FVIII; Xyntha; Pfizer, New York, NY, USA) were used to create a standard curve for measuring FVIII:C levels.
Fibrinogen levels were determined with ELISA, as previously described [24] .
Immunohistochemistry
Anesthetized mice were perfused with 20 mL of PBS through the left ventricle. The liver was removed, fixed in 10% formalin, and embedded in paraffin. After rehydration, antigen retrieval, peroxidase blocking, and protein blocking, sections were incubated overnight with goat antimouse fibrinogen antibody (Nordic Immunological Laboratories, Susteren, the Netherlands) in a humidified chamber. Anti-goat IgG peroxidase (Vector Laboratories, Burlingame, CA, USA) was used as secondary antibody for 30 min. Antigen-antibody complexes were visualized with ImmPACT DAB Peroxidase Substrate (Vector Laboratories), and counterstained with hematoxylin and eosin. To assess in vivo clot formation, we modified a previously reported protocol [25] . Briefly, the right carotid artery of anesthetized mice was exposed. A 1 9 2-mm filter paper (Whatman no. 1; GE Healthcare, Pittsburgh, PA, USA) soaked in 20% ferric chloride (Sigma Aldrich) was applied to the carotid artery, and removed after 3 min, and the surface of the artery was carefully washed three times with warm PBS to remove residual ferric chloride. A Doppler ultrasound flow probe (Model MA0.5PSB; Transonic Systems, Ithaca, NY, USA) was placed on the artery to monitor blood flow after injury. Time to occlusion (TTO) of the carotid artery was defined as the time from removal of the filter paper to a lack of blood flow for three consecutive minutes. The maximum observation time was 45 min.
Whole blood coagulation assays
Thrombin generation in whole blood was determined with our recently reported native whole blood thrombin generation assay (nWB-TGA) [21] . Briefly, 15 lL of whole blood drawn from the IVC was recalcified without the addition of tissue factor, in the presence of a rhodamine-based, thrombin-cleavable, fluorescent substrate (Invitrogen, Carlsbad, CA, USA). The reaction mixture was added to a filter paper disk placed in a 96-dark-well plate. The increase in fluorescence was monitored over time, and thrombin generation was calculated with Technothrombin TGA evaluation software (Technoclone, Vienna, Austria), based on a calibration experiment performed with a thrombin standard. Whole blood clot formation was determined by rotational thromboelastometry (ROTEM) (TEM Systems, Muenchen, Germany). ROTEM minicups were preloaded with 7 lL of 0.2 M CaCl 2 , 105 lL of whole blood was added, and clot formation was recorded over a period of 90 min with the NATEM assay function.
Assessment of platelet activation by whole blood flow cytometry
Whole blood drawn from the IVC (2 lL) was carefully combined with the indicated concentrations of ADP (Chronolog, Havertown, PA, USA), mouse proteaseactivated receptor 4 (PAR4) ligand (Gly-Tyr-Pro-GlyLys-Phe-NH 2 , GYPGKF-NH 2 ; made in-house by our protein core facilities), or Tyrode buffer as control, and the following antibodies: Dylight 649-conjugated antimouse GPIb, phycoerythrin (PE)-conjugated anti-mouse CD41 (clone: JON/A), and fluorescein isothiocyanateconjugated anti-mouse P-selectin (all antibodies were from Emfret, Eibelstadt, Germany). To determine the levels of platelet-leukocyte aggregates (PLAs), whole blood was combined with 20 lM ADP, 1 mM PAR4, or Tyrode buffer as control, and the following antibodies: allophycocyanin-eFluor 780-conjugated anti-mouse CD45.2 (eBioscience, San Diego, CA, USA), and PE-conjugated anti-mouse integrin aIIb (GPIIb; Santa Cruz Biotechnology, Dallas, TX, USA). Reaction mixtures (final volume of 40 lL) were incubated at room temperature in the dark for 20 min and quenched with a 10-fold excess volume of Tyrode buffer. Data were acquired on an LSRII flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA), and evaluated with FLOWJO X10 software (FlowJo, Ashland, OR, USA).
Statistical analysis
Statistical analysis was performed with GRAPHPADPRISM 4 (GraphPad Software, La Jolla, CA, USA). Statistical differences between groups were determined with the nonparametric Mann-Whitney test or Student's t-test. The chi-square test was used to assess the Mendelian distribution of mouse genotypes. All data are presented as mean AE standard deviation. A P-value of < 0.05 was considered to be statistically significant.
Results
Characterization of a transgenic mouse model expressing supratherapeutic levels of FVIII in platelets
In order to evaluate a potential thrombotic risk associated with platelet-expressed FVIII (2bF8), we developed a transgenic mouse model expressing higher 2bF8 levels than we were previously able to achieve. To accomplish this, we crossed two founder lines, LV17 tg and LV18 tg , which we obtained by lentivirus-mediated transgenesis. We previously described LV18 tg mice as having a single transgene inserted into the deoxyribonuclease 1-like 2 gene on chromosome 17 [21] . LV17 tg mice also carried a single insert of the transgene, but in a different chromosomal location than LV18 tg mice. In LV17 tg mice, the transgene was integrated into the oxysterol-binding protein-like protein 7 gene on chromosome 11. Both lines were on a FVIII-deficient background. LV18 tg mice expressed FVIII at 11.7 AE 1.1 mU per 10 8 platelets when homozygous [21] . LV17 tg mice expressed FVIII at 6.9 AE 1.7 mU per 10 8 platelets when homozygous. When the two lines were crossed, the resulting LV17/18 tg mice expressed FVIII at 23.4 AE 2.4 mU per 10 8 platelets when homozygous for both traits (Fig. 1 ). This 2bF8 level was approximately 30-fold higher than therapeutically required to restore hemostasis in our originally described 2bF8 trans mouse line (0.75 mU per 10 8 platelets) [7] , and allowed evaluation of the thrombotic risk associated with supratherapeutic levels of platelet-expressed FVIII.
Mice expressing high levels of 2bF8 do not show signs of increased thrombotic risk under steady-state conditions
To evaluate the thrombotic risk in LV17/18 tg mice, we first determined the levels of plasma parameters that have been associated with an increased thrombotic risk and compared them with those in WT control mice. Fibrinogen and D-dimer levels were similar in WT and LV17/ 18 tg mice ( Fig. 2A,B) . TAT levels were significantly increased in LV17/18 tg mice as compared with WT mice, and FVIII-deficient mice also had similarly increased levels of TAT as LV17/18 tg mice. This suggests that the FVIII-deficient background rather than 2bF8 might be the cause of this increase (Fig. 2C) . Next, we used whole blood assays to determine whether thrombin generation or ex vivo clot formation was increased in LV17/18 tg mice. Using our previously reported [21] determined by ROTEM in WT and LV17/18 tg mice, respectively, were 424 AE 54 s and 705 AE 91 s, and maximum clot firmness values were 51.3 AE 3.7 mm and 54.0 AE 4.1 mm (Table 1) . Thus, under steady-state conditions, platelet-expressed FVIII did not appear to be prothrombotic with either approach.
Supratherapeutic levels of platelet-expressed FVIII do not enhance in vivo clot formation
To determine whether 2bF8 increases in vivo thrombus formation above WT levels, we subjected mice to ferric chloride-induced carotid artery injury. TTO after vessel injury in LV17/18 tg mice was 10.6 AE 3.0 min, and was not statistically different from that in WT mice (6.7 AE 1.6 min). In contrast, vessels in F8 null mice did not occlude throughout the entire 45-min observation period (Table 1) . Thus, 2bF8 does not increase in vivo clot formation above that observed in WT mice, and does correct the clotting time in the ferric chloride injury model.
Inflammation does not induce an abnormal thrombotic risk in mice with supratherapeutic levels of platelet-expressed FVIII Upregulation of acute-phase cytokines during inflammation has been shown to induce a prothrombotic state [26] [27] [28] [29] . To determine whether 2bF8 increased the thrombotic risk under prothrombotic conditions, we subjected LV17/ 18 tg and WT mice to LPS challenge. Fluid injections were provided as supportive care to normalize the HCT in LPS-challenged mice (Fig. 3A) . The decrease in platelet counts upon LPS challenge, indicating the first signs of disseminated intravascular coagulopathy, was similar in WT and LV17/18 tg mice (Fig. 3B) . Fibrinogen, D-dimer and TAT levels were similarly increased in WT and LV17/18 tg mice during inflammation. After LPS challenge, fibrinogen levels were increased 1.6-fold in WT mice and 1.3-fold in LV17/18 tg mice (Fig. 3C ), D-dimer levels were increased 14.7-fold in WT mice and eight-fold in LV17/18 tg mice (Fig. 3D) , and TAT levels were increased 3.3-fold in WT mice and 2.2-fold in LV17/18 tg mice (Fig. 3E) . Fibrinogen, D-dimer and TAT levels were not statistically significantly different between LV17/18 tg and WT mice after LPS challenge (Fig. 3C-E) . Fibrin deposition upon LPS challenge appeared to be similar in livers of WT and LV17/18 tg mice, whereas no fibrin deposition was observed in PBS-treated control mice (Fig. 3F) . In summary, 2bF8 did not induce an increased thrombotic risk under LPS-induced inflammatory conditions.
Platelet-expressed FVIII does not increase the FVL prothrombotic phenotype
Activated protein C resistance resulting from the FVL mutation (human, R506Q; mouse, R504Q) substantially increases the thrombotic risk in homozygous carriers for both humans and mice [23, 30] . To evaluate the effect of supratherapeutic platelet-FVIII levels in the thrombosissensitizing background, LV18 tg mice that expressed FVIII at approximately 12 mU per 10 8 platelets were crossed onto the prothrombotic FVL background in addition to 100% of endogenous mouse plasma FVIII. In striking contrast to heterozygous tissue factor pathway inhibitor ) or TAT (10.5 AE 2.4 ng mL À1 ) levels (Fig. 4B,C ). These data demonstrate that 2bF8 does not induce an increased thrombotic risk in a pre-existing thrombosis-prone background.
Normal platelet function in mice with supratherapeutic levels of platelet-expressed FVIII
We finally investigated whether platelets expressing FVIII were hyperactivated or hyperactivatable upon agonist stimulation as compared with WT platelets. We employed a whole blood flow cytometry-based assay to evaluate activation of aIIbb 3 by using the PE-conjugated JON/A antibody, which specifically binds to the activated form of the integrin [32] , and we used P-selectin expression on platelets to evaluate the a-granule exocytosis pathway. Without stimulation, the frequencies and mean fluorescence intensity (MFI) of JON/A binding and P-selectin staining showed similar background levels on WT and LV17/18 tg platelets. Stimulation with increasing concentrations of PAR4 agonist dose-dependently increased aIIbb 3 activation and P-selectin expression. ADP stimulation, on the other hand, induced aIIbb 3 activation but not P-selectin expression (Fig. 5A) . Significantly higher frequencies and MFIs of JON/A binding upon ADP stimulation were observed in LV17/18 tg platelets than in WT platelets, which were of mixed C57BL6/129S background (Fig. 5B,C) . A similar trend for JON/A binding was found after stimulation with PAR4 agonist (Fig. 5B) . P-selectin expression upon PAR4 agonist stimulation was overall comparable between LV17/18 tg and WT platelets, with the exception that 0.5 mM PAR4 agonist induced a higher frequency of P-selectin-expressing platelets (Fig. 5D,E) . Although LV17/18 tg platelets appeared to be hyperactivatable as compared with mixed-background (C57BL6/129S) WT platelets, the activation level of LV17/18 tg platelets under all stimulation conditions was similar to or lower than the activation level of WT platelets from a different colony of mice that were on a pure C57BL6 background (Fig. 5B,C,E) .
Activated platelets bind to leukocytes and form PLAs [33, 34] . Monitoring of PLAs has been suggested for assessment of thrombosis [35] . The level of PLAs was 7% in normal murine whole blood, and was similar in LV17/18 tg and WT mice under steady-state conditions. Whereas stimulation with ADP did not increase PLA levels, PAR4 agonist significantly increased PLA levels to the same extent in LV17/18 tg and WT mice (Fig. 6A,B) . Together, our data show that platelets expressing supratherapeutic levels of FVIII are not hyperactivated or hyperactivateable as compared with WT platelets.
Discussion
Platelet-targeted FVIII gene therapy has been proven to restore hemostasis in preclinical HA models [6] [7] [8] [9] [10] [11] [12] [13] [14] . As ) express platelet FVIII. All mice also expressed 100% endogenous plasma FVIII. *P < 0.05, ***P < 0.001 (Student's t-test). NS, not significant. platelets have fundamental roles not only in hemostasis but also in thrombosis, it is important to evaluate whether there are potential pathologic consequences associated with platelet-targeted FVIII expression as a means of gene therapy for HA before considering this approach for clinical application. In this study, we demonstrate that supratherapeutic levels of FVIII expressed in platelets by the aIIb promoter appear to be non-thrombogenic under both steady-state and prothrombotic conditions induced by LPS-mediated inflammation or the FVL mutation. Furthermore, targeting FVIII expression to platelets does not induce platelet hyperactivation or hyperresponsiveness. tg platelets appeared to be hyperactivated as compared with platelets from mixed 129S/C57BL6 background WT mice, platelet activation in LV17/18 tg mice under all stimulation conditions was similar or lower than that in WT mice on a pure C57BL6 background. Significance levels between WT and L17/18 tg samples are indicated. *P < 0.05, **P < 0.01, ***P < 0.001(Student's t-test). GP, glycoprotein.
We have previously reported that, in a transgenic mouse model, FVIII expression of 0.75 mU per 10 8 platelets restored hemostasis on a hemophilic background [7] . For the clinically applicable gene therapy protocol, ex vivo transduction of bone marrow with a lentivirus carrying the 2bF8 gene cassette and transplantation of transduced bone marrow into preconditioned hosts is required. Owing to transduction and gene expression efficiency, expression levels of 2bF8 may vary between individuals. In an attempt to define the breadth of the therapeutic window, we here developed transgenic mice that expressed FVIII at 23.4 mU per 10 8 platelets, which is an approximately 30-fold higher platelet-expressed FVIII level than is therapeutically required. We subjected these mice to a variety of methods for the assessment of a prothrombotic state, including nWB-TGA, ex vivo whole blood clot formation analysis with ROTEM, in vivo clot formation upon ferric chloride-induced carotid artery injury, and tissue fibrin deposition. We also evaluated plasma parameters associated with increased thrombosis risk, including D-dimer [36] [37] [38] [39] , TAT [40] , and fibrinogen [25] . None of these assays and parameters, with the exception of TAT levels, was elevated over WT levels in LV17/18 tg mice under steady-state conditions. TAT levels in LV17/18 tg mice were approximately double those in WT mice. We also detected increased TAT levels in FVIII null mice; these were similar to the levels obtained in LV17/18 tg mice, and we therefore attributed the increase in TAT levels to the FVIII-deficient background. Other studies have not reported increased TAT levels in HA or hemophilia B mice as compared with WT mice [41, 42] . The different outcomes from those in our studies might be attributable to mouse strain differences and/or differences in plasma preparation. Plasma for TAT measurement was obtained by tail clipping in the aforementioned studies, and this might have impacted on sample activation. We obtained plasma by IVC draw, which is considered to be the blood-drawing method in mice that results in least activated blood, owing to minimal tissue factor contamination and platelet activation [43] . In our studies, samples drawn from the IVC showed little activation, which was confirmed by a low von Willebrand factor (VWF) propeptide/VWF antigen ratio (< 0.5, data not shown). The VWF propeptide/VWF antigen ratio is an indicator of sample activation mainly through platelet activation, with a ratio of < 0.5 indicating very little to no sample activation [44] . Low-level activation in other studies might mask the differences in TAT levels that we found in our study.
To determine whether 2bF8 increases the thrombotic risk under prothrombotic conditions, we applied two different approaches. Both inflammation and the FVL mutation have been shown to induce a prothrombotic state in humans and preclinical models [23, 28, 30, 45] . We challenged mice with LPS to induce inflammation, and in a second approach we backcrossed 2bF8 onto the prothrombotic FVL background. As expected, we detected increased levels of fibrinogen, D-dimer and TAT, and increased tissue fibrin deposition, after LPS challenge in WT mice. The FVL mutation, an R506Q mutation in the FV gene, resulted, as expected, in increased levels of D-dimer and TAT on an otherwise WT background. Importantly, these levels were not further increased by 2bF8, even in FVL mice that additionally expressed endogenous FVIII. These data demonstrate that 2bF8 does not appear to be thrombogenic even under prothrombotic conditions.
Hyperactivation and hyperactivatability of platelets increase the thrombotic risk [46, 47] . We found that platelet activation determined by P-selectin exposure and aIIbb 3 activation under steady-state conditions (without stimulation) was similar whether or not platelets expressed FVIII. PAR4 agonist and ADP stimulation of whole blood dose-dependently increased platelet activation. Although we observed higher platelet activation in LV17/18 tg mice than in 129S/C57BL6 mixed-background WT mice, platelet activation in LV17/18 tg mice was lower than or similar to that in WT mice on a pure C57BL6 background. Mouse strain-specific differences in platelet responsiveness have been reported [48] . Platelets from 129S mice appeared to be less sensitive to agonist stimulation than platelets from C57BL6 mice. It is possible that, in our 129S/C57BL6 mixed-background LV17 tg and LV18 tg transgenic founder colonies, which have been maintained in our facility for several generations, genetic traits affecting platelet activation, specifically PAR4 and ADP signaling, were preferentially propagated from the C57BL6 background. Whether signaling pathways resulting in platelet activation triggered by agonists other than PAR4 agonist or ADP show similar differences is unclear. The exact mechanism and potential differentially expressed molecules involved in platelet signaling and activation in different mouse strains have yet to be determined.
It has been reported that platelet-targeted gene therapy directed by the GPIb promoter induces apoptosis in megakaryocytes, resulting in a 30% reduction in platelet counts after therapy [49] . However, the platelet number fully recovered after bone marrow reconstitution with 2bF8 gene therapy, in which FVIII expression is driven by the aIIb promoter [12] . Apart from demonstrating that 2bF8 does not hyperactivate platelets, our studies show that 2bF8 does not impair platelet function as assessed with whole blood flow cytometry, whether we used weak or strong platelet activation. Our data are in agreement with those from studies performed by Damon et al. [50] , who showed that FVIII expression under the control of the platelet-specific platelet factor 4 promoter did not impair phosphatidylserine exposure or P-selectin expression upon stimulation with strong platelet agonists (thrombin or ionophore).
In conclusion, in the current study, we have demonstrated that supratherapeutic levels of 2bF8, which are 30-fold in excess of the 2bF8 levels required for restoring hemostasis in hemophilic mice, appear to be non-thrombogenic and do not induce platelet hyperactivation or hyperresponsiveness. We have shown that, even under prothrombotic conditions induced by inflammation or FVL, platelet-targeted FVIII expression is not associated with increased thrombogenicity in mice. Thus, with regard to thrombotic risk, platelet-targeted FVIII gene therapy does not appear to raise safety concerns, and seems to have a relatively wide therapeutic window. Targeting FVIII expression to platelets represents a promising approach to permanently restore hemostasis in patients with HA, but this needs to be tested in clinical trials. Even patients with coexisting thrombophilic disorders need not be excluded from platelet-targeted gene therapy. 
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